Abstract Purpose Posaconazole (POS) is widely used as an antifungal agent effective against Candida infections. Because of its very low water and high fat solubility, it falls under the Biopharmaceutics Classification System (BCS) Class…

Abstract Purpose The main purpose of this study is to synthesize posaconazole as a nanosponge device to evaluate its antifungal potential, specifically for the treatment of cutaneous candidiasis caused by the Candida albicans fungus.…

Abstract Invasive pulmonary aspergillosis poses a significant threat to immunocompromised patients, characterized by high mortality rates. Posaconazole (PSZ), a second-generation triazole antifungal, exhibits broad-spectrum activity but…

Abstract Purpose Posaconazole (PSZ) is BCS class-II drug that displays variable bioavailability upon oral administration due to extremely low and pH-dependent solubility. Method The present investigation was aimed to formulate and…

Four model polymers, representing (i) amorphous homopolymers (Kollidon K30, K30), (ii) amorphous heteropolymers (Kollidon VA64, KVA), (iii) semi-crystalline homopolymers (Parteck MXP, PXP), and (iv) semi-crystalline heteropolymers…

Current study intended to prepare and evaluate phospholipid-based, mixed micelles (MMs) to improve the ocular delivery of posaconazole (POS), a broad-spectrum antifungal drug. For this, MMs based on egg phosphatidylcholine (EPC), as the…

Background: Fungal ocular infections can cause serious consequences, despite their low incidence. It has been reported that Posaconazole (PSC) is used in the treatment of fungal infections in different ocular tissues by diluting the oral…

Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical…

Amorphous solid dispersions (ASDs) can increase bioavailability of drugs with poor aqueous solubility. However, concentration-sustaining dispersion polymers (CSPs) incorporated in ASDs can result in low drug loading and therefore large…

Poor aqueous solubility is a major challenge for formulation scientists as more than 40% of new chemical entities developed in the pharmaceutical industry are insoluble in water. The high energy amorphous form offers enhanced solubility and…